Curiteva, a medical expertise firm, has efficiently handled greater than 5,000 ranges utilizing the Encourage Cervical implant, simply two years after its first surgical use in April 2023. This milestone highlights the continued adoption of the novel 3D printed trabecular PEEK implant.
“I’ve seen outstanding radiographic proof with the Encourage platform, together with seen bone development inside the graft window and thru the implant inside simply 3 to six months. This gives clinicians with an unparalleled capability to evaluate therapeutic and progress reliably,” stated Chambliss Harrod, MD from The Backbone Middle of Louisiana.
“With this implant, I usually require little to no bracing and have considerably better confidence in each fusion charges and affected person satisfaction throughout multilevel ACDF procedures,” stated John Johnson, MD from SportsMed Orthopedic Surgical procedure and Backbone Middle in Alabama.
“After utilizing Allograft for 30+ years, I’ve lastly discovered a viable substitute for bone. These Curiteva implants have the potential to revolutionize not solely backbone care but additionally a variety of different functions the place beforehand bone might need been used. This expertise has set a brand new normal in affected person care by way of its modern design and distinctive biomechanical and potential organic properties,” stated Mark N. Hadley, MD from the College of Alabama Division of Neurosurgery in Birmingham, Alabama.
Engineered with Curiteva’s proprietary and internally developed FFF 3D printers, Encourage implants characteristic a totally interconnected and built-in porous construction traversing the complete implant. Mixed with its HAFUSE sub-micron nano-texturing, the Encourage implant promotes through-growth, making a superior organic atmosphere for bone integration.
Curiteva plans a full business launch after a profitable alpha launch of the Encourage TLIF Anterior and Encourage TLIF Indirect implants later this month. Moreover, the corporate is about to roll out alpha launches for its ALIF portfolio, encompassing Monolithic, Thoracolumbar Plate, and Standalone implants later this yr.
“These achievements replicate the synergy of modern expertise, world-class manufacturing, vibrant partnerships, and medical belief,” stated Chad Falciani, Founder and Chairman of the Board at Curiteva.
